Posted: Monday, August 22, 2022
According to Christian W. Scholz, MD, of Charité–Universitätsmedizin Berlin, and colleagues, at a median follow-up of 30.6 months, radioimmunotherapy with yttrium 90–labeled ibritumomab tiuxetan (Y-90–IT) demonstrated “promising” results in patients with follicular lymphoma. The long-term follow-up data from this international, multicenter phase II trial, which were published in the Annals of Hematology, continue to support this radioimmunotherapy as an effective and safe upfront treatment in this population.
A total of 59 patients older than age 50 with stage II to IV disease underwent radioimmunotherapy with Y-90–IT. About 6 months after completion of treatment, those who achieved a complete response without evidence of measurable residual disease (MRD), partial response, or stable disease were observed. Patients who achieved a complete response with MRD positivity were administered consolidation therapy with rituximab. Follow-up data were provided for a median of 9.6 years.
The median duration of progression-free survival was 3.6 years, and the 8-year progression-free survival rate was 38.3%. The median duration of overall survival was not reached; the 8-year overall survival rate was 69.2%. Factors found to be associated with shorter duration of overall survival were older age (≥ 65 years) and disease progression within 24 months of treatment. No new safety signals were observed. In addition, compared with trials with a similar follow-up, there did not seem to be an increase in the incidence of secondary malignancies or transformation into aggressive lymphoma.
“Our data…prompt further trials of novel antibody-radionuclide conjugates as front-line treatment of follicular lymphoma,” the investigators concluded.
Disclosure: For full disclosures of the study authors, visit ncbi.nlm.nih.gov.